Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.

A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas

Open access

Abstract

Glioblastoma Multiforme (GBM), the most common and lethal primary human brain tumor, exhibits multiple molecular aberrations. We report that loss of the transcription factor GATA4, a negative regulator of normal astrocyte proliferation, is a driver in glioma formation and fulfills the hallmarks of a tumor suppressor gene (TSG). Although GATA4 was expressed in normal brain, loss of GATA4 was observed in 94/163 GBM operative samples and was a negative survival prognostic marker. GATA4 loss occurred through promoter hypermethylation or novel somatic mutations. Loss of GATA4 in normal human astrocytes promoted high-grade astrocytoma formation, in cooperation with other relevant genetic alterations such as activated Ras or loss of TP53. Loss of GATA4 with activated Ras in normal astrocytes promoted a progenitor-like phenotype, formation of neurospheres, and the ability to differentiate into astrocytes, neurons, and oligodendrocytes. Re-expression of GATA4 in human GBM cell lines, primary cultures, and brain tumor–initiating cells suppressed tumor growth in vitro and in vivo through direct activation of the cell cycle inhibitor P21CIP1, independent of TP53. Re-expression of GATA4 also conferred sensitivity of GBM cells to temozolomide, a DNA alkylating agent currently used in GBM therapy. This sensitivity was independent of MGMT (O-6-methylguanine-DNA-methyltransferase), the DNA repair enzyme which is often implicated in temozolomide resistance. Instead, GATA4 reduced expression of APNG (alkylpurine-DNA-N-glycosylase), a DNA repair enzyme which is poorly characterized in GBM-mediated temozolomide resistance. Identification and validation of GATA4 as a TSG and its downstream targets in GBM may yield promising novel therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20102099

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. GATA4 loss in GBM. (A) Loss of Gata4 observed in primary astrocyte cultures from transgenic mice bearing GBM tumors at 3 mo (RasB8 P3) compared with primary astrocyte cultures from healthy newborn pups RasB8 P0 and astrocyte cultures from newborn or adult healthy WT mice NMA). (B) Immunoblotting of GATA4, GATA5 in human GBM cell lines with NHB, NHAs, and immortalized NHAs with telomerase (NHA + hTERT) used as positive controls. (C and D) Immunohistochemical analysis of GATA4 in normal brain (n = 10, positive control), low grade gliomas (n = 29; C), and GBM operative specimens (n = 163; D) with corresponding H&E stains. (E) Survival curve analysis of GATA4-positive and -negative GATA4 GBM patients (Log-Rank test, P = 0.01). Bars: (C) 20 µm; (D) 50 µm. Western blots were performed in triplicate.
Figure 1. GATA4 loss in GBM. (A) Loss of Gata4 observed in primary astrocyte cultures from transgenic mice bearing GBM tumors at 3 mo (RasB8 P3) compared with primary astrocyte cultures from healthy newborn pups RasB8 P0 and astrocyte cultures from newborn or adult healthy WT mice NMA). (B) Immunoblotting of GATA4, GATA5 in human GBM cell lines with NHB, NHAs, and immortalized NHAs with telomerase (NHA + hTERT) used as positive controls. (C and D) Immunohistochemical analysis of GATA4 in normal brain (n = 10, positive control), low grade gliomas (n = 29; C), and GBM operative specimens (n = 163; D) with corresponding H&E stains. (E) Survival curve analysis of GATA4-positive and -negative GATA4 GBM patients (Log-Rank test, P = 0.01). Bars: (C) 20 µm; (D) 50 µm. Western blots were performed in triplicate.CC BY-NC-SA · PubMed Central
Figure 2. Promoter methylation and mutations result in loss of GATA4 expression. (A) GATA4 proximal promoter (−1,000 bp from transcriptional start site) contains two CpG islands. Dashed arrow show location of MSP-PCR primers and nondashed arrows show location of primers used for bisulfite sequencing. MSP-PCR of GATA4 in GBM cell lines, NHB, and NHAs is shown. Methylated product (M) and unmethylated product (U) are indicated. (B) GBM cell lines were treated with 5-aza-2’-deoxycytidine (5 µm final concentration, abbreviated ± A for 96 h) and GATA4 protein measured by Western blot. (C) Bisulfite sequencing represented as a heat map demonstrates that lack of GATA4 transcript corresponds with high promoter methylation of GATA4 (Met+ group) versus UMet+ group (P = 0.0001). GBMs from the unmethylated cohort (Umet+ group) that did not have GATA4 transcript or high promoter methylation were subjected to exon sequencing in E. (D) GATA4 promoter-luciferase construct was transfected in NHA and GBM cell lines and measured for luciferase activity over 72 h. A 600-bp product of the GATA4 luciferase promoter was amplified using PCR and analyzed for methylation by bisulfite sequencing. The percentage of methylation is listed below the bar graph for 24 and 72 h (*, P < 0.001). (E) Somatic GATA4 mutations identified in GBM samples from C. (F) Schematic, location of GATA4 mutations, Zinc finger (Zn), nuclear localization sequence (nls), and transactivation domain (TAD). Introduction of mutations into WT GATA4 by site directed mutagenesis are shown. These mutant constructs were cotransfected into U87 cells with a P21-CIP1 luciferase construct containing two GATA responsive elements. Luciferase readings were measured 24 h after transfection and compared with WT GATA4 and negative controls with mean and SEM reported (*, P < 0.05). All experiments were performed in triplicate, with D and E showing the mean ± SEM. Bisulfite sequencing analysis was determined by sequencing of 10–15 individual clones per sample.
Figure 2. Promoter methylation and mutations result in loss of GATA4 expression. (A) GATA4 proximal promoter (−1,000 bp from transcriptional start site) contains two CpG islands. Dashed arrow show location of MSP-PCR primers and nondashed arrows show location of primers used for bisulfite sequencing. MSP-PCR of GATA4 in GBM cell lines, NHB, and NHAs is shown. Methylated product (M) and unmethylated product (U) are indicated. (B) GBM cell lines were treated with 5-aza-2’-deoxycytidine (5 µm final concentration, abbreviated ± A for 96 h) and GATA4 protein measured by Western blot. (C) Bisulfite sequencing represented as a heat map demonstrates that lack of GATA4 transcript corresponds with high promoter methylation of GATA4 (Met+ group) versus UMet+ group (P = 0.0001). GBMs from the unmethylated cohort (Umet+ group) that did not have GATA4 transcript or high promoter methylation were subjected to exon sequencing in E. (D) GATA4 promoter-luciferase construct was transfected in NHA and GBM cell lines and measured for luciferase activity over 72 h. A 600-bp product of the GATA4 luciferase promoter was amplified using PCR and analyzed for methylation by bisulfite sequencing. The percentage of methylation is listed below the bar graph for 24 and 72 h (*, P < 0.001). (E) Somatic GATA4 mutations identified in GBM samples from C. (F) Schematic, location of GATA4 mutations, Zinc finger (Zn), nuclear localization sequence (nls), and transactivation domain (TAD). Introduction of mutations into WT GATA4 by site directed mutagenesis are shown. These mutant constructs were cotransfected into U87 cells with a P21-CIP1 luciferase construct containing two GATA responsive elements. Luciferase readings were measured 24 h after transfection and compared with WT GATA4 and negative controls with mean and SEM reported (*, P < 0.05). All experiments were performed in triplicate, with D and E showing the mean ± SEM. Bisulfite sequencing analysis was determined by sequencing of 10–15 individual clones per sample.CC BY-NC-SA · PubMed Central
Figure 3. Loss of GATA4 promotes transformation. (A) NHAs expressing activated Ras were transfected with control or GATA4-specific shRNA, with or without an shRNA-resistant GATA4 construct (GATA4 rescue). Left, GATA4 expression measured by Western blotting. Right, BrdU incorporation measured on indicated days. *, P = 0.02. (B) NOD-SCID mice were subjected to intracranial xenograft with cells described in A. Brains were analyzed by IHC. 0/5 mice injected with shRNA control developed tumors (top left). All other panels refer to mice injected with GATA4 shRNA1 (5/5). Bars: (top row, left and middle) 500 µm; (middle row, left) 50 µm; (all others) 25 µm. (C) Expression of indicated surface markers was quantified from staining shown in B from five mice. Mean and SEM are represented. (D) Cells described in A were cultured in neural progenitor growth conditions for days. Representative neurospheres are shown. *, P < 0.0001. (E) Neurospheres from D were cultured under conditions promoting differentiation into astrocytes (indicated by GFAP expression), neurons (indicated by TUJ1 expression), and oligodendrocytes (indicated by O4 expression). Cells were stained with the indicated antibodies, DAPI, and nuclear stain. Bar, 16 µm. A, D, and E were performed in triplicate with mean and SEM reported where appropriate. B and C are representative stains from five mice.
Figure 3. Loss of GATA4 promotes transformation. (A) NHAs expressing activated Ras were transfected with control or GATA4-specific shRNA, with or without an shRNA-resistant GATA4 construct (GATA4 rescue). Left, GATA4 expression measured by Western blotting. Right, BrdU incorporation measured on indicated days. *, P = 0.02. (B) NOD-SCID mice were subjected to intracranial xenograft with cells described in A. Brains were analyzed by IHC. 0/5 mice injected with shRNA control developed tumors (top left). All other panels refer to mice injected with GATA4 shRNA1 (5/5). Bars: (top row, left and middle) 500 µm; (middle row, left) 50 µm; (all others) 25 µm. (C) Expression of indicated surface markers was quantified from staining shown in B from five mice. Mean and SEM are represented. (D) Cells described in A were cultured in neural progenitor growth conditions for days. Representative neurospheres are shown. *, P < 0.0001. (E) Neurospheres from D were cultured under conditions promoting differentiation into astrocytes (indicated by GFAP expression), neurons (indicated by TUJ1 expression), and oligodendrocytes (indicated by O4 expression). Cells were stained with the indicated antibodies, DAPI, and nuclear stain. Bar, 16 µm. A, D, and E were performed in triplicate with mean and SEM reported where appropriate. B and C are representative stains from five mice.CC BY-NC-SA · PubMed Central
Figure 4. Re-expression of GATA4 suppresses cell proliferation and in vivo tumor growth. (A) Transient expression of GATA4 under a constitutive active CMV promoter or empty vector control (EV) decreases proliferation in several GBM cell lines of varying genetic backgrounds. *, P < 0.01 (B) Transient expression of GATA4 leads to attenuation of cyclin D1 with increased levels of P21CIP1 and P15INK4B. (C and D) Doxycycline was added to U87 GBM cell line expressing GATA4 under a doxycycline-inducible promoter. (C) At indicated time points, GATA4, P21CIP1, and CCND1 were measured by Western blotting. (D) At the indicated times, cells in culture were counted. *, P = 0.001. (E) Survival curve of NOD-SCID mice were injected with intracranial xenografts of U87 cells with GATA4 under doxycycline (DOX)-inducible promoter. Mice were continually given doxycycline in drinking water (GATA4 on, n = 10) or no doxycycline (GATA4 off, n = 10). (F) Immunohistochemical analysis of protein markers from tumors of mice not given dox (no GATA4) versus mice given dox (GATA4). Bars: (first H&E column) 500 µm; (second [magnified] H&E column) 50 µm; (GATA4, P21-CIP1, and ki67 columns) 25 µm. (G) Quantification of protein staining from F. n = 5 mice. *, P < 0.01. Mean and SEM are shown. A and D were performed in triplicate with mean and SEM reported.
Figure 4. Re-expression of GATA4 suppresses cell proliferation and in vivo tumor growth. (A) Transient expression of GATA4 under a constitutive active CMV promoter or empty vector control (EV) decreases proliferation in several GBM cell lines of varying genetic backgrounds. *, P < 0.01 (B) Transient expression of GATA4 leads to attenuation of cyclin D1 with increased levels of P21CIP1 and P15INK4B. (C and D) Doxycycline was added to U87 GBM cell line expressing GATA4 under a doxycycline-inducible promoter. (C) At indicated time points, GATA4, P21CIP1, and CCND1 were measured by Western blotting. (D) At the indicated times, cells in culture were counted. *, P = 0.001. (E) Survival curve of NOD-SCID mice were injected with intracranial xenografts of U87 cells with GATA4 under doxycycline (DOX)-inducible promoter. Mice were continually given doxycycline in drinking water (GATA4 on, n = 10) or no doxycycline (GATA4 off, n = 10). (F) Immunohistochemical analysis of protein markers from tumors of mice not given dox (no GATA4) versus mice given dox (GATA4). Bars: (first H&E column) 500 µm; (second [magnified] H&E column) 50 µm; (GATA4, P21-CIP1, and ki67 columns) 25 µm. (G) Quantification of protein staining from F. n = 5 mice. *, P < 0.01. Mean and SEM are shown. A and D were performed in triplicate with mean and SEM reported.CC BY-NC-SA · PubMed Central
Figure 5. GATA4 negatively regulates GBM growth. (A) Western blot demonstrating protein levels of GATA4, P21-CIP, CCND1, and APNG in T98G cells under varying treatments. MGMT was used as a loading control. (B) BrdU assay of T98G cells by modulation of GATA4, P21-CIP, or CCND1. *, P < 0.01 (ANOVA). (C) GATA4-mediated sensitivity to 100 µm temozolomide in vitro (T98G cells; *, P = 0.001, ANOVA). Cell death under non-temozolomide was statistically insignificant (P > 0.05, ANOVA). (D, Top) qRT-PCR GATA4 expression in brain tumor initiating cells G144, G179 compared with NHAs, normal neural stem cells (NSC), and the embryonic stem cell line (H9). (D, Bottom) Western blot assessing GATA4 protein status in the lines mentioned for D, Top. *, P > 0.05. (E) qRT-PCR of neural stem cell markers in G179 cells. Cells were grown in neural stem cell media. *, P < 0.01. (F) qRT-PCR of the lineage markers, GFAP (astrocytic), NKX2.2 (oligodendrocytic), and TUBB3 (neuronal). *, P < 0.01 in G179 cells. Cells were placed in differentiation conditions (neural stem cell media + 1% fetal bovine serum) for 12 d before RNA extraction. All experiments were performed in triplicate with mean and SEM reported.
Figure 5. GATA4 negatively regulates GBM growth. (A) Western blot demonstrating protein levels of GATA4, P21-CIP, CCND1, and APNG in T98G cells under varying treatments. MGMT was used as a loading control. (B) BrdU assay of T98G cells by modulation of GATA4, P21-CIP, or CCND1. *, P < 0.01 (ANOVA). (C) GATA4-mediated sensitivity to 100 µm temozolomide in vitro (T98G cells; *, P = 0.001, ANOVA). Cell death under non-temozolomide was statistically insignificant (P > 0.05, ANOVA). (D, Top) qRT-PCR GATA4 expression in brain tumor initiating cells G144, G179 compared with NHAs, normal neural stem cells (NSC), and the embryonic stem cell line (H9). (D, Bottom) Western blot assessing GATA4 protein status in the lines mentioned for D, Top. *, P > 0.05. (E) qRT-PCR of neural stem cell markers in G179 cells. Cells were grown in neural stem cell media. *, P < 0.01. (F) qRT-PCR of the lineage markers, GFAP (astrocytic), NKX2.2 (oligodendrocytic), and TUBB3 (neuronal). *, P < 0.01 in G179 cells. Cells were placed in differentiation conditions (neural stem cell media + 1% fetal bovine serum) for 12 d before RNA extraction. All experiments were performed in triplicate with mean and SEM reported.CC BY-NC-SA · PubMed Central
Figure 6. P21CIP1 is a direct target of GATA4. (A) ChIP assay of GATA4. GATA4 is enriched in P21CIP1 promoter regions containing GATA binding elements (top, U87 cells). (B) P21-CIP1 luciferase construct wt or constructs with GATA sites mutated were transfected into U87 cells with or without WT GATA4. Luciferase readings were taken 48 h after transfection. *, P < 0.001. GATA fails to activate luciferase expression when both GATA sites are mutated (MS1 and MS2). *, P < 0.001 compared with WT control P21-luciferase construct. (C and D) Silencing of P21CIP1 with overexpression of GATA4 rescues the antiproliferation effect of GATA4 but not to parental levels. *, P < 0.001; **, P = 0.002. Loss of P21CIP1 by itself further increases proliferation in U87 cells. ***, P < 0.001. (E) Western blot demonstrating overexpression of GATA4, loss of P53, and changes to P21-CIP1 levels. Doxorubicin was used to activate TP53. (F) P21-CIP1 luciferase assay in U373 cells (mutant TP53), and GATA4 and WT TP53 lead to a synergistic increase of luciferase expression. *, P = 0.001, lane 5 compared with lanes 2 and 3. Experiments were performed in triplicate with mean and SEM reported.
Figure 6. P21CIP1 is a direct target of GATA4. (A) ChIP assay of GATA4. GATA4 is enriched in P21CIP1 promoter regions containing GATA binding elements (top, U87 cells). (B) P21-CIP1 luciferase construct wt or constructs with GATA sites mutated were transfected into U87 cells with or without WT GATA4. Luciferase readings were taken 48 h after transfection. *, P < 0.001. GATA fails to activate luciferase expression when both GATA sites are mutated (MS1 and MS2). *, P < 0.001 compared with WT control P21-luciferase construct. (C and D) Silencing of P21CIP1 with overexpression of GATA4 rescues the antiproliferation effect of GATA4 but not to parental levels. *, P < 0.001; **, P = 0.002. Loss of P21CIP1 by itself further increases proliferation in U87 cells. ***, P < 0.001. (E) Western blot demonstrating overexpression of GATA4, loss of P53, and changes to P21-CIP1 levels. Doxorubicin was used to activate TP53. (F) P21-CIP1 luciferase assay in U373 cells (mutant TP53), and GATA4 and WT TP53 lead to a synergistic increase of luciferase expression. *, P = 0.001, lane 5 compared with lanes 2 and 3. Experiments were performed in triplicate with mean and SEM reported.CC BY-NC-SA · PubMed Central
Figure 7. GATA4 sensitizes GBM cells to temozolomide. (A and B) GATA4 sensitizes T98G and U87 cells to temozolomide. *, P < 0.01 from 40–500 µm. (C) Immunoblotting shows GATA4 in presence of temozolomide increased cleaved PARP with no changes in MGMT observed. GATA4 reduces levels of the DNA repair enzyme APNG in GBM cell lines and primary xenograft GBM cultures. (D) Stable GATA4 expression in MGMT-expressing T98G cells or GBM6 xenograft cells led to reduced levels of APNG and increased levels of cleaved PARP when exposed to temozolomide. (E) Immunoblot showing MGMT and APNG knockdown when treated with siRNA compared with controls in T98G cells. (F) Trypan blue cell death assay of APNG, MGMT, or combination knockdown compared with siRNA controls. *, P < 0.0001 in T98G cells. A, B, and F were performed in triplicate with SEM reported. Experiments in C–E were performed in triplicate with representative Western blot shown.
Figure 7. GATA4 sensitizes GBM cells to temozolomide. (A and B) GATA4 sensitizes T98G and U87 cells to temozolomide. *, P < 0.01 from 40–500 µm. (C) Immunoblotting shows GATA4 in presence of temozolomide increased cleaved PARP with no changes in MGMT observed. GATA4 reduces levels of the DNA repair enzyme APNG in GBM cell lines and primary xenograft GBM cultures. (D) Stable GATA4 expression in MGMT-expressing T98G cells or GBM6 xenograft cells led to reduced levels of APNG and increased levels of cleaved PARP when exposed to temozolomide. (E) Immunoblot showing MGMT and APNG knockdown when treated with siRNA compared with controls in T98G cells. (F) Trypan blue cell death assay of APNG, MGMT, or combination knockdown compared with siRNA controls. *, P < 0.0001 in T98G cells. A, B, and F were performed in triplicate with SEM reported. Experiments in C–E were performed in triplicate with representative Western blot shown.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Kleihues, 2000, World Health Organization Classification of Tumors: Pathology and Genetic: Tumors of the Nervous System

Cited by

See all 96

Metadata

Authors
Agnihotri, S., Wolf, A., Munoz, D. M., Smith, C. J., Gajadhar, A., Restrepo, A., Clarke, I. D., Fuller, G. N., Kesari, S., Dirks, P. B., McGlade, C. J., Stanford, W. L., Aldape, K., Mischel, P. S., Hawkins, C., & Guha, A.
Affiliations
  • University of Toronto (CA)
  • The Arthur and Sonia Labatt’s Brain Tumor Research Centre, The Hospital for Sick Children’s Research Institute 1 , 2 , 3 , and 4
  • The University of Texas MD Anderson Cancer Center (US)
  • University of California San Diego (US)
  • University of California, Los Angeles (US)
Corresponding author
Guha, Abhijit
Venue
Journal of Experimental Medicine
Published
2011-04-04
Volume
208
Issue
4
Pages
689-702
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2167377849
Cited by
92
References
53
Citations by year
2026: 3 · 2025: 9 · 2024: 1 · 2023: 4 · 2022: 10 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 2 · 2013: 10 · 2012: 9
FWCI
4.38
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
Keywords
GATA4, glioblastoma, astrocytoma, tumor suppressor, transcription factors, promoter hypermethylation, Ras activation, p53 deficiency, p21 Cip1, temozolomide sensitivity, MGMT, DNA repair, cancer stem cells, neurospheres, cell cycle inhibition, prognostic factors
MeSH terms
Temozolomide, Animals, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Promoter Regions, Genetic, DNA Modification Methylases, DNA Methylation, Cyclin D1, Tumor Suppressor Proteins, DNA Repair Enzymes, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, GATA4 Transcription Factor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. https://app.cochat.ai/papers/10.1084/jem.20102099
The paper
Agnihotri, S., Wolf, A., Munoz, D. M., Smith, C. J., Gajadhar, A., Restrepo, A., Clarke, I. D., Fuller, G. N., Kesari, S., Dirks, P. B., McGlade, C. J., Stanford, W. L., Aldape, K., Mischel, P. S., Hawkins, C., & Guha, A. (2011). A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20102099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.